A commonly prescribed medication for attention-deficit hyperactivity disorder (ADHD) has been recalled nationwide after failing to meet dissolution standards during laboratory testing.

According to an enforcement report from the Food and Drug Administration (FDA) , Sun Pharmaceutical Industries Inc. initiated a voluntary recall on Oct. 28 for its lisdexamfetamine dimesylate capsules, a generic alternative to the brand-name drug Vyvanse.

The recall affects multiple dosage strengths of the stimulant medication, which is prescribed to improve focus in patients with ADHD. It can also be prescribed to treat Binge Eating Disorder (BED), per the FDA .

The FDA classified the action as a Class II recall on Oct. 30, indicating the medication could cause temporary or medically reversible hea

See Full Page